

Aegerion Pharmaceuticals 2017 Methodology Document - ABPI Disclosure Reporting

Tax/VAT considerations:	Yearly amounts for each reportable HCP/HCO included VAT, where applicable.
Currency Aspects (including conversion rates):	All reported amounts are in British pounds. If the payment was made in another currency, the Company calculated the amount into British pounds using the OANDA conversion rate at the date of payment.
Cross Border Payments:	The Company included identified payments made to UK HCPs/HCOs from the US-based parent company (Aegerion, Inc.) or any of the Company's subsidiaries including Aegerion's UK-based subsidiary (Aegerion Ltd.). For payments that run over the calendar year, it is reported in the year the activity took place.
Multi-year contracts:	The Company reported all payments made to the reported HCPs/HCOs in calendar year 2017. If a contract contemplated payments to be made in subsequent calendar years, those payments will be reflected in those subsequent calendar years' filings.
Over-the-counter transfers of value:	N/A
Consent:	The contracts for the reported HCPs/HCOs included, with few exceptions, consent language in the contract between the Company and the reported HCP/HCO. The Company did not require consent to be obtained in a stand-alone document. If consent was not explicit in any HCP/HCO contract, the Company received written consent prior to Aegerion's 2017 ABPI filing from the reported HCPs/HCOs.